Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal

Hansa Biopharma AB

11/11/2026 06:10

Overview
Sweden biopharma firm's Q3 revenue surged on SERB licensing deal
Company ended Q3 with higher cash after €110 mln SERB upfront payment
First commercial Idefirix patient treated in Australia during the quarter

Outlook
Company preparing for potential US launch of imlifidase, subject to regulatory approval
Hansa to continue advancing HNSA-5487 in Guillain-Barré syndrome clinical development
Company says revenue composition will change due to SERB licensing agreement

Result Drivers
SERB LICENSE REVENUE - Q3 revenue was primarily driven by license revenue recognized under the agreement with SERB Pharmaceuticals
REVENUE COMPOSITION SHIFT - Co said revenue composition changed significantly due to licensing of Idefirix to SERB, making revenue not directly comparable to prior periods

Company press release: ID:nWkr688372

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
 
SEK 143 mln
 
Q3 Adjusted Loss Per Share
 
SEK 1.75
 
Q3 Net Loss
 
SEK 178.50 mln
 
Q3 Cash & Investments
 
SEK 1.34 bln
 
Q3 EBIT
 
-SEK 138.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Hansa Biopharma AB is SEK72.00, about 84.9% above its November 10 closing price of SEK38.94

Reuters Recommended Reads
Nov 9 - UK's Mereo BioPharma Q3 revenue beats expectations
Nov 10 - Italy's Recordati 9M revenue rises on strong Rare Diseases business momentum
Nov 10 - Scholar Rock posts first product revenue after ISEMBYLD launch

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)